Abstract
Heat Shock Protein 70 (HSP70) functions as a molecular chaperone to prevent the misfolding and aggregation of proteins under stressful conditions. Geranylgeranylacetone (GGA) is a pharmacologic inducer of HSP70 in the absence of heat stress, making GGA a potential candidate for post‐heat injury/stroke (HI/S) therapy. We hypothesized that GGA administered 24h post‐HI/S would augment liver HSP70 gene expression and accelerate HI/S recovery in rats. Male F344 rats (277.5 ± 5.3 g) were orally administered GGA (200 mg/kg bw; n=9) or vehicle (Veh; 1mL; n=9) 24h post‐HI/S (Tc,Max, 41.8°C; radiotelemetry). GGA had no effect on thermal load accrued during heat exposure. Liver HSP70 gene expression (qPCR) and biomarkers of liver function (VetScan; ALT, albumin, bile acids, BUN) were examined at 2 and 10d of recovery. Liver HSP70 gene expression was increased ~2000‐fold through 10d of recovery; GGA had no effect on this response. Bile acids, ALT and BUN were similar between HI/S and non‐heated controls on 2 and 10d regardless of treatment. Conversely, HI/S rats treated with GGA showed significantly lower albumin levels compared to non‐heated controls at 2d (4.24±0.07 v 4.78±0.03 U/L, respectively; ANOVA, p<0.01). Our results suggest that GGA administration 24h post‐HI/S is not an efficacious treatment in rats and may delay recovery of liver function. Research supported by MRMC. Author views not official US Army or DoD policy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call